Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

Rhea-AI Impact

(High)

Rhea-AI Sentiment

(Positive)

Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) announced preclinical data showing intranasal anti-CD3 (foralumab) reversed key aspects of brain aging and improved cognition in an aging model.

Findings report reduced microglial activation, enhanced hippocampal neurogenesis, and lowered cellular senescence markers, supporting further clinical development in neurodegenerative indications.

Positive

Reversed brain aging features in preclinical aging model
Improved cognition observed in study subjects
Reduced microglial activation linked to neuroinflammation
Enhanced hippocampal neurogenesis important for memory
Lowered cellular senescence markers and age-related gene expression

Negative

Evidence limited to preclinical models; human clinical efficacy not demonstrated
No quantitative clinical endpoints or numerical effect sizes reported in the announcement

News Market Reaction – TLSA

+6.84%

3 alerts

+6.84% News Effect

+4.8% Peak Tracked

+$10M Valuation Impact

$149.35M Market Cap

0.0x Rel. Volume

On the day this news was published, TLSA gained 6.84%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.8% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $10M to the company's valuation, bringing the market cap to $149.35M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $1.2500 Vol: Volume 226,991 is 1.54x t...

high vol

$1.2500 Last Close

Volume Volume 226,991 is 1.54x the 20-day average, indicating elevated trading interest ahead of this update. high

Technical Shares at $1.17 are trading below the 200-day MA of $1.69 and about 55% under the 52-week high.

Peers on Argus

TLSA fell 5.65% while close biotech peers showed mixed moves (e.g., KYTX up 11.3...

2 Up 1 Down

TLSA fell 5.65% while close biotech peers showed mixed moves (e.g., KYTX up 11.35%, TRDA up 4.13%, VYGR down 1.03%). Scanner momentum names were split between gains and losses, reinforcing this as stock-specific rather than a broad sector reaction.

Historical Context

5 past events · Latest: Feb 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	Biomarker data	Positive	+4.5%	na‑SPMS biomarker data showed reduced microglial activation and improved CSF profile.
Jan 20	Study publication	Positive	-6.0%	Peer‑reviewed na‑SPMS study publication with clinical stabilization and PET improvements.
Jan 16	Financing closed	Neutral	+15.9%	Closing of $8.8M registered direct offering with attached warrants and insider participation.
Jan 16	Financing priced	Neutral	+15.9%	Pricing of registered direct offering to raise ~$8.0M plus warrant upside for trials.
Jan 09	Conference presentation	Neutral	-3.4%	Announcement of neuroscience forum presentation focused on intranasal foralumab.

Pattern Detected

News on foralumab’s biology and clinical data has produced mixed reactions, while insider-led financings saw stronger positive moves.

Recent Company History

Over recent months, Tiziana has repeatedly highlighted intranasal foralumab, from biomarker data in na‑SPMS on Feb 25, 2026 to a peer‑reviewed publication on Jan 20, 2026. Two insider‑participated offerings on Jan 16, 2026 raised about $8–8.8M and were followed by ~15.9% stock gains, despite dilution. Conference participation and mechanism‑focused updates in early January drew modest negative reactions. Today’s aging/neuroinflammation preclinical data fits the ongoing narrative of immune‑modulating, intranasal anti‑CD3 for neurodegenerative conditions.

Market Pulse Summary

The stock moved +6.8% in the session following this news. A strong positive reaction aligns with pri...

Analysis

The stock moved +6.8% in the session following this news. A strong positive reaction aligns with prior episodes where mechanism‑focused or financing news around intranasal foralumab led to sizeable gains, such as moves of ~4.5% and ~15.9% after earlier data and offerings. However, past dilution events and the stock’s position well below its 52‑week high of $2.60 highlight ongoing capital needs and volatility that could temper or reverse enthusiasm as new data and funding steps emerge.

Key Terms

anti-CD3, monoclonal antibody, microglial activation, neuroinflammation, +3 more

7 terms

anti-CD3 medical

"intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces"

An anti‑CD3 is an antibody drug that binds to the CD3 protein on T cells, the immune system’s frontline soldiers, to change how those cells behave. Think of it like attaching a remote control to specific immune cells to dial their activity up, down or redirect them; for investors, anti‑CD3 therapies signal a drug class with significant promise in autoimmune diseases, transplant protection and certain cancer strategies, but also carry clinical, regulatory and safety risks that strongly influence valuation and trial outcomes.

monoclonal antibody medical

"intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

microglial activation medical

"Nasal anti-CD3 dampens microglial activation that drives chronic neuroinflammation."

Microglial activation is when the brain’s resident immune cells — microglia — switch from a resting, maintenance role into an alert, defensive state, similar to a neighborhood cleanup crew suddenly racing to douse a small fire. For investors, this matters because persistent or excessive activation is a hallmark of many neurological diseases, affects how drugs perform in trials, and can drive regulatory and market reactions to therapies aimed at calming or harnessing this response.

neuroinflammation medical

"novel approach to address neuroinflammation associated with aging, which contributes"

Neuroinflammation is the brain or spinal cord’s immune reaction to injury, infection, or abnormalities, where cells and molecules become active to protect or repair nervous tissue. It matters to investors because it underlies many neurological diseases and is a common target for drugs and diagnostic tools; positive or negative trial results, safety signals, or new therapies can change a company’s value much like a major repair plan or recall would affect a carmaker’s prospects.

neurogenesis medical

"Nasal anti-CD3 enhances neurogenesis in the hippocampus, a region critical"

The growth of new nerve cells in the brain and nervous system, a process that helps repair damage, form memories, and maintain brain function. For investors, neurogenesis matters because drugs or therapies that reliably boost or protect this process can signal potential treatments for conditions like memory loss, depression, or neurodegenerative diseases, which may affect market value, regulatory review, and long-term revenue prospects. Think of it as the brain’s ability to plant and nurture new seedlings that keep a garden healthy.

cellular senescence medical

"and reduces cellular senescence by down regulating inflammatory markers"

Cells enter cellular senescence when they stop dividing but remain alive and active, often releasing signals that alter nearby tissue and immune responses. Because these “retired” but noisy cells can drive aging, chronic inflammation and tissue dysfunction, therapies and tests that remove, calm or detect them are promising areas of medical research and investment—potentially creating new treatment markets, diagnostic tools and long‑term healthcare savings.

regulatory T cells medical

"foralumab, which stimulates regulatory T cells that reduce neuroinflammation"

Regulatory T cells are a specialized type of immune cell that act like a brake on the body’s defense system, preventing it from attacking healthy tissue or causing chronic inflammation. They matter to investors because drugs that increase or block these cells can change treatment success and safety in areas such as autoimmune disease, organ transplants, and cancer immunotherapy, affecting clinical trial results, approval chances, and commercial value.

AI-generated analysis. Not financial advice.

04/01/2026 - 07:00 AM

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces positive preclinical data highlighting nasal anti-CD3’s potential as a novel approach to address neuroinflammation associated with aging, which contributes to cognitive decline in age-related disorders. In the study, nasal anti-CD3 reversed key aspects of brain aging, and improved cognition.

Key study findings:

Nasal anti-CD3 dampens microglial activation that drives chronic neuroinflammation. This reduction in inflammation, which is strongly linked to cognitive decline, suggests the therapy could help mitigate the inflammatory burden and slow aspects of the aging process.
Nasal anti-CD3 enhances neurogenesis in the hippocampus, a region critical for learning and memory and reduces cellular senescence by down regulating inflammatory markers and age-related genes.

“These preclinical results are highly encouraging and build on our growing body of evidence that nasal foralumab modulates the immune system to reduce neuroinflammation,” said Howard L. Weiner, M.D., Chairman of Tiziana’s Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital. “By targeting T cells to influence microglial behavior and promote brain repair mechanisms like neurogenesis, nasal anti-CD3 offers a differentiated, non-invasive approach with potential applications in age related cognitive impairment.”

“These aging model findings reinforce the mechanism of action of intranasal foralumab, which stimulates regulatory T cells that reduce neuroinflammation,” said Ivor Elrifi, CEO of Tiziana Life Sciences. “Tiziana continues to advance its clinical programs for intranasal foralumab, including ongoing trials in Non-Active Secondary Progressive Multiple Sclerosis, MSA, ALS, Alzheimer’s disease, and other neurodegenerative indications, while expanding preclinical research into additional areas such as aging.”

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biologic candidate that has been shown to stimulate T regulatory cells when dosed intranasally. Currently, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]^,[3]

About Tiziana Life Sciences

Tiziana is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Tiziana's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Tiziana's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Tiziana cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of Tiziana only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Tiziana will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
[3] https://www.neurology.org/doi/10.1212/NXI.0000000000200543

FAQ

What did Tiziana (TLSA) announce on April 1, 2026 about nasal anti-CD3 and cognition?

Tiziana announced preclinical results showing nasal anti-CD3 reversed aging-related brain changes and improved cognition. According to Tiziana, the study showed reduced microglial activation and increased hippocampal neurogenesis in an aging model.

How does intranasal foralumab (TLSA) affect neuroinflammation in the April 2026 study?

Intranasal foralumab reduced microglial activation that drives chronic neuroinflammation. According to Tiziana, this dampening of inflammation is associated with markers linked to cognitive decline in aging.

Did the April 1, 2026 announcement report human clinical results for TLSA's nasal anti-CD3?

No, the announcement described preclinical (animal/model) findings rather than human clinical results. According to Tiziana, clinical programs remain ongoing for multiple neurodegenerative indications.

What cognitive benefits did the April 2026 preclinical study claim for TLSA's nasal anti-CD3?

The study reported improved cognition and enhanced hippocampal neurogenesis in the aging model. According to Tiziana, these changes align with mechanisms that support learning and memory.

Which programs does Tiziana (TLSA) say it is advancing after the April 2026 preclinical findings?

Tiziana is advancing intranasal foralumab clinical programs in Non-Active SPMS, MSA, ALS, and Alzheimer’s disease. According to Tiziana, trials in these neurodegenerative indications are ongoing while preclinical research expands into aging.

Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging